The potential diagnostic value of serum microRNA signature in patients with pancreatic cancer

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

The potential diagnostic value of serum microRNA signature in patients with pancreatic cancer. / Johansen, Julia S; Calatayud, Dan; Albieri, Vanna; Schultz, Nicolai A; Dehlendorff, Christian; Werner, Jens; Jensen, Benny V; Pfeiffer, Per; Bojesen, Stig E; Giese, Nathalia; Nielsen, Kaspar R; Nielsen, Svend E; Yilmaz, Mette Karen; Holländer, Niels H; Andersen, Klaus K.

In: International Journal of Cancer, Vol. 139, No. 10, 15.11.2016, p. 2312-24.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Johansen, JS, Calatayud, D, Albieri, V, Schultz, NA, Dehlendorff, C, Werner, J, Jensen, BV, Pfeiffer, P, Bojesen, SE, Giese, N, Nielsen, KR, Nielsen, SE, Yilmaz, MK, Holländer, NH & Andersen, KK 2016, 'The potential diagnostic value of serum microRNA signature in patients with pancreatic cancer', International Journal of Cancer, vol. 139, no. 10, pp. 2312-24. https://doi.org/10.1002/ijc.30291

APA

Johansen, J. S., Calatayud, D., Albieri, V., Schultz, N. A., Dehlendorff, C., Werner, J., Jensen, B. V., Pfeiffer, P., Bojesen, S. E., Giese, N., Nielsen, K. R., Nielsen, S. E., Yilmaz, M. K., Holländer, N. H., & Andersen, K. K. (2016). The potential diagnostic value of serum microRNA signature in patients with pancreatic cancer. International Journal of Cancer, 139(10), 2312-24. https://doi.org/10.1002/ijc.30291

Vancouver

Johansen JS, Calatayud D, Albieri V, Schultz NA, Dehlendorff C, Werner J et al. The potential diagnostic value of serum microRNA signature in patients with pancreatic cancer. International Journal of Cancer. 2016 Nov 15;139(10):2312-24. https://doi.org/10.1002/ijc.30291

Author

Johansen, Julia S ; Calatayud, Dan ; Albieri, Vanna ; Schultz, Nicolai A ; Dehlendorff, Christian ; Werner, Jens ; Jensen, Benny V ; Pfeiffer, Per ; Bojesen, Stig E ; Giese, Nathalia ; Nielsen, Kaspar R ; Nielsen, Svend E ; Yilmaz, Mette Karen ; Holländer, Niels H ; Andersen, Klaus K. / The potential diagnostic value of serum microRNA signature in patients with pancreatic cancer. In: International Journal of Cancer. 2016 ; Vol. 139, No. 10. pp. 2312-24.

Bibtex

@article{44b58e97002847e49cb09564acc2811f,

title = "The potential diagnostic value of serum microRNA signature in patients with pancreatic cancer",

abstract = "Biomarkers for early diagnosis of patients with pancreatic cancer (PC) are needed. Our aim was to identify panels of miRNAs in serum in combination with CA 19-9 for use in the diagnosis of PC. Four hundred seventeen patients with PC were included prospectively from Denmark (n = 306) and Germany (n = 111). Controls included 59 patients with chronic pancreatitis (CP) and 248 healthy subjects (HS). MiRNAs were analyzed in pretreatment serum samples from 3 cohorts: discovery cohort (754 human miRNAs, TaqMan({\textregistered}) Human MicroRNA assay, Applied Biosystem; PC n = 133, controls n = 72); training cohort (34 miRNAs, real-time qPCR using the Fluidigm BioMark{\texttrademark} System; PC n = 198, controls n = 184); validation cohort (13 miRNAs, real-time qPCR using the Fluidigm BioMark{\texttrademark} System; PC n = 86, controls n = 51). We found that 34 miRNAs in serum from PC patients in the discovery cohort were expressed differently than in controls. These miRNAs were tested in the training cohort, and four diagnostic panels were constructed that included 5 or 12 miRNAs (miR-16, -18a, -20a, -24, -25, -27a, -29c, -30a.5p, -191, -323.3p, -345 and -483.5p). Diagnostic accuracy of detecting PC in the training cohort was AUC (Index I 0.85; II 0.87; III 0.85; IV 0.95; CA 19-9 0.93); specificity (I 0.71; II 0.76; III 0.66; IV 0.90 (fixed sensitivity at 0.85); CA 19-9 0.93). Combining serum CA 19-9 and Index II best discriminated Stages I and II PC from HS [AUC 0.93 (0.90-0.96), sensitivity 0.77 (0.69-0.84), specificity 0.94 (0.90-0.96) and accuracy 0.88 (0.84-0.91)]. In conclusion, we identified four diagnostic panels based on 5 or 12 miRNAs in serum that could distinguish patients with PC from HS and CP.",

keywords = "Carcinoma, Pancreatic Ductal, Case-Control Studies, Humans, MicroRNAs, Pancreatic Neoplasms, Pancreatitis, Chronic, Reproducibility of Results, Journal Article",

author = "Johansen, {Julia S} and Dan Calatayud and Vanna Albieri and Schultz, {Nicolai A} and Christian Dehlendorff and Jens Werner and Jensen, {Benny V} and Per Pfeiffer and Bojesen, {Stig E} and Nathalia Giese and Nielsen, {Kaspar R} and Nielsen, {Svend E} and Yilmaz, {Mette Karen} and Holl{\"a}nder, {Niels H} and Andersen, {Klaus K}",

note = "{\textcopyright} 2016 UICC.",

year = "2016",

month = nov,

day = "15",

doi = "10.1002/ijc.30291",

language = "English",

volume = "139",

pages = "2312--24",

journal = "International Journal of Cancer",

issn = "0020-7136",

publisher = "JohnWiley & Sons, Inc.",

number = "10",

}

RIS

TY - JOUR

T1 - The potential diagnostic value of serum microRNA signature in patients with pancreatic cancer

AU - Johansen, Julia S

AU - Calatayud, Dan

AU - Albieri, Vanna

AU - Schultz, Nicolai A

AU - Dehlendorff, Christian

AU - Werner, Jens

AU - Jensen, Benny V

AU - Pfeiffer, Per

AU - Bojesen, Stig E

AU - Giese, Nathalia

AU - Nielsen, Kaspar R

AU - Nielsen, Svend E

AU - Yilmaz, Mette Karen

AU - Holländer, Niels H

AU - Andersen, Klaus K

PY - 2016/11/15

Y1 - 2016/11/15

N2 - Biomarkers for early diagnosis of patients with pancreatic cancer (PC) are needed. Our aim was to identify panels of miRNAs in serum in combination with CA 19-9 for use in the diagnosis of PC. Four hundred seventeen patients with PC were included prospectively from Denmark (n = 306) and Germany (n = 111). Controls included 59 patients with chronic pancreatitis (CP) and 248 healthy subjects (HS). MiRNAs were analyzed in pretreatment serum samples from 3 cohorts: discovery cohort (754 human miRNAs, TaqMan(®) Human MicroRNA assay, Applied Biosystem; PC n = 133, controls n = 72); training cohort (34 miRNAs, real-time qPCR using the Fluidigm BioMark™ System; PC n = 198, controls n = 184); validation cohort (13 miRNAs, real-time qPCR using the Fluidigm BioMark™ System; PC n = 86, controls n = 51). We found that 34 miRNAs in serum from PC patients in the discovery cohort were expressed differently than in controls. These miRNAs were tested in the training cohort, and four diagnostic panels were constructed that included 5 or 12 miRNAs (miR-16, -18a, -20a, -24, -25, -27a, -29c, -30a.5p, -191, -323.3p, -345 and -483.5p). Diagnostic accuracy of detecting PC in the training cohort was AUC (Index I 0.85; II 0.87; III 0.85; IV 0.95; CA 19-9 0.93); specificity (I 0.71; II 0.76; III 0.66; IV 0.90 (fixed sensitivity at 0.85); CA 19-9 0.93). Combining serum CA 19-9 and Index II best discriminated Stages I and II PC from HS [AUC 0.93 (0.90-0.96), sensitivity 0.77 (0.69-0.84), specificity 0.94 (0.90-0.96) and accuracy 0.88 (0.84-0.91)]. In conclusion, we identified four diagnostic panels based on 5 or 12 miRNAs in serum that could distinguish patients with PC from HS and CP.

AB - Biomarkers for early diagnosis of patients with pancreatic cancer (PC) are needed. Our aim was to identify panels of miRNAs in serum in combination with CA 19-9 for use in the diagnosis of PC. Four hundred seventeen patients with PC were included prospectively from Denmark (n = 306) and Germany (n = 111). Controls included 59 patients with chronic pancreatitis (CP) and 248 healthy subjects (HS). MiRNAs were analyzed in pretreatment serum samples from 3 cohorts: discovery cohort (754 human miRNAs, TaqMan(®) Human MicroRNA assay, Applied Biosystem; PC n = 133, controls n = 72); training cohort (34 miRNAs, real-time qPCR using the Fluidigm BioMark™ System; PC n = 198, controls n = 184); validation cohort (13 miRNAs, real-time qPCR using the Fluidigm BioMark™ System; PC n = 86, controls n = 51). We found that 34 miRNAs in serum from PC patients in the discovery cohort were expressed differently than in controls. These miRNAs were tested in the training cohort, and four diagnostic panels were constructed that included 5 or 12 miRNAs (miR-16, -18a, -20a, -24, -25, -27a, -29c, -30a.5p, -191, -323.3p, -345 and -483.5p). Diagnostic accuracy of detecting PC in the training cohort was AUC (Index I 0.85; II 0.87; III 0.85; IV 0.95; CA 19-9 0.93); specificity (I 0.71; II 0.76; III 0.66; IV 0.90 (fixed sensitivity at 0.85); CA 19-9 0.93). Combining serum CA 19-9 and Index II best discriminated Stages I and II PC from HS [AUC 0.93 (0.90-0.96), sensitivity 0.77 (0.69-0.84), specificity 0.94 (0.90-0.96) and accuracy 0.88 (0.84-0.91)]. In conclusion, we identified four diagnostic panels based on 5 or 12 miRNAs in serum that could distinguish patients with PC from HS and CP.

KW - Carcinoma, Pancreatic Ductal

KW - Case-Control Studies

KW - Humans

KW - MicroRNAs

KW - Pancreatic Neoplasms

KW - Pancreatitis, Chronic

KW - Reproducibility of Results

KW - Journal Article

U2 - 10.1002/ijc.30291

DO - 10.1002/ijc.30291

M3 - Journal article

C2 - 27464352

VL - 139

SP - 2312

EP - 2324

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 10

ER -

ID: 176866479